Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients

被引:31
|
作者
Kim, Dong Wook [1 ,2 ]
Kim, Hyoung Jung [1 ,2 ]
Kim, Kyung Won [1 ,2 ]
Byun, Jae Ho [1 ,2 ]
Kim, So Yeon [1 ,2 ]
Song, Ki Byung [3 ]
Ramaiya, Nikhil H. [4 ]
Tirumani, Sree Harsha [4 ]
Hong, Seung-Mo [5 ]
机构
[1] Univ Ulsan, Coll Med, Dept Radiol, 86 Asanbyeongwon Gil, Seoul 138736, South Korea
[2] Univ Ulsan, Coll Med, Res Inst Radiol, Asan Med Ctr, 86 Asanbyeongwon Gil, Seoul 138736, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul 138736, South Korea
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging,Brigham & Womens Hosp, 44 Binney St, Boston, MA 02115 USA
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul 138736, South Korea
关键词
Pancreas; Neuroendocrine neoplasm; Overall survival; Recurrence free survival; CT; ENDOCRINE TUMORS; MICROVASCULAR DENSITY; HELICAL CT; ADENOCARCINOMA; CLASSIFICATION; EXPRESSION; FEATURES; SYSTEM; CANCER; MDCT;
D O I
10.1007/s00330-015-3943-5
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To evaluate the prognostic value of CT to predict recurrence-free and overall survival in patients with pancreatic neuroendocrine neoplasms (PanNENs). Methods Between January 2004 and December 2012, 161 consecutive patients who underwent preoperative triphasic CT and surgical resection with curative intent for PanNENs were identified. The tumour consistency, margin, presence of calcification, pancreatic duct dilatation, bile duct dilatation, vascular invasion, and hepatic metastases were evaluated. The tumour size, arterial enhancement ratio, and portal enhancement ratio were measured. The Cox proportional hazard model was used to determine the association between CT features and recurrence-free survival and overall survival. Results By multivariate analysis, tumour size (> 3 cm) (hazard ratio, 3.314; p = 0.006), portal enhancement ratio (a parts per thousand currency sign1.1) (hazard ratio, 2.718; p = 0.006), and hepatic metastases (hazard ratio, 4.374; p = 0.003) were independent significant variables for worse recurrence-free survival. Portal enhancement ratio (a parts per thousand currency sign1.1) (hazard ratio, 5.951; p = 0.001) and hepatic metastases (hazard ratio, 4.122; p = 0.021) were independent significant variables for worse overall survival. Conclusions Portal enhancement ratio (a parts per thousand currency sign1.1) and hepatic metastases assessed on CT were common independent prognostic factors for worse recurrence-free survival and overall survival in patients with PanNENs.
引用
收藏
页码:1320 / 1329
页数:10
相关论文
共 50 条
  • [41] Prognostic value of tumor-to-parenchymal contrast enhancement ratio on portal venous-phase CT in pancreatic neuroendocrine neoplasms
    Park, Hyo Jung
    Kim, Hyoung Jung
    Kim, Jung Hoon
    Kim, So Yeon
    Choi, Sang Hyun
    Byun, Jae Ho
    Kim, Song Cheol
    Hwang, Hee Sang
    Hong, Seung-Mo
    EUROPEAN RADIOLOGY, 2023, 33 (04) : 2713 - 2724
  • [42] Prognostic value of tumor-to-parenchymal contrast enhancement ratio on portal venous-phase CT in pancreatic neuroendocrine neoplasms
    Hyo Jung Park
    Hyoung Jung Kim
    Jung Hoon Kim
    So Yeon Kim
    Sang Hyun Choi
    Jae Ho Byun
    Song Cheol Kim
    Hee Sang Hwang
    Seung-Mo Hong
    European Radiology, 2023, 33 : 2713 - 2724
  • [43] Survival disparities in rural versus urban patients with pancreatic neuroendocrine tumor: A multi-institutional study from the US neuroendocrine tumor study group
    Mirza, Muhammad Bilal
    Baechle, Jordan J.
    Smith, Paula Marincola
    Dillhoff, Mary
    Poultsides, George
    Rocha, Flavio G.
    Cho, Clifford S.
    Winslow, Emily R.
    Fields, Ryan C.
    Maithel, Shishir K.
    Idrees, Kamran
    AMERICAN JOURNAL OF SURGERY, 2024, 233 : 125 - 131
  • [44] Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM
    Ingenerf, Maria
    Karim, Homeira
    Auernhammer, Christoph
    Zacherl, Matthias
    Wenter, Vera
    Winkelmann, Michael
    Ricke, Jens
    Berger, Frank
    Schmid-Tannwald, Christine
    RADIOLOGY AND ONCOLOGY, 2023, 57 (04) : 436 - 445
  • [45] Evaluation of Prognostic Factors that Affect Survival Outcomes of Breast Cancer Patients with Brain Metastases: A Single Institutional Experience
    Patil, Roshankumar
    Pandit, Prakash
    Palwe, Vijay
    Kate, Shruti
    Gandhe, Sucheta
    Patil, Rahul
    Ramesh, Yasam Venkata
    Nagarkar, Raj
    EUROPEAN JOURNAL OF BREAST HEALTH, 2021, 17 (01) : 62 - 67
  • [46] Development and validation of a simple-to-use nomogram to predict liver metastasis in patients with pancreatic neuroendocrine neoplasms: a large cohort study
    Maoen Pan
    Yuanyuan Yang
    Tianhong Teng
    Fengchun Lu
    Yanchan Chen
    Heguang Huang
    BMC Gastroenterology, 21
  • [47] Development and validation of a simple-to-use nomogram to predict liver metastasis in patients with pancreatic neuroendocrine neoplasms: a large cohort study
    Pan, Maoen
    Yang, Yuanyuan
    Teng, Tianhong
    Lu, Fengchun
    Chen, Yanchan
    Huang, Heguang
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [48] The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro-Entero-Pancreatic (GEP-NEN) System
    Gebauer, Niklas
    Ziehm, Maria
    Gebauer, Judith
    Riecke, Armin
    Meyhoefer, Sebastian
    Kulemann, Birte
    von Bubnoff, Nikolas
    Steinestel, Konrad
    Bauer, Arthur
    Witte, Hanno M.
    CANCERS, 2022, 14 (21)
  • [49] A prognostic nomogram based on log odds of positive lymph nodes to predict the overall survival in biliary neuroendocrine neoplasms (NENs) patients after surgery
    Jiang, S.
    Yang, F.
    Zhang, L.
    Sang, X.
    Lu, X.
    Zheng, Y.
    Xu, Y.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (12) : 2341 - 2351
  • [50] A prognostic nomogram based on log odds of positive lymph nodes to predict the overall survival in biliary neuroendocrine neoplasms (NENs) patients after surgery
    S. Jiang
    F. Yang
    L. Zhang
    X. Sang
    X. Lu
    Y. Zheng
    Y. Xu
    Journal of Endocrinological Investigation, 2022, 45 : 2341 - 2351